A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical Tomotherapy for 1-3 Brain Metastases
NCT ID: NCT01543542
Last Updated: 2016-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
91 participants
INTERVENTIONAL
2010-04-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain Metastases
NCT02220491
Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases
NCT00168129
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
NCT00550654
Receiving Radiation Therapy in the MRgRT Research Facility
NCT02701712
5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases
NCT01761929
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Radiation Therapy Treatment
Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
Whole Brain XRT 30Gy/10 fractions with
30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Whole Brain XRT 30Gy/10 fractions with
30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Contrast enhanced MRI demonstrating 1-3 metastases within 6 weeks of enrollment
* Age greater than or equal to 18
* Karnofsky performance status greater than or equal to 70
* Patient available for subsequent follow-up appointments and testing as well as health-related quality of life questionnaires
* Anticipated survival (independent of the brain metastases) greater than 3 months
* Patient informed consent obtained
* Metastatic suitable for synchronous boost
* Extracranial disease controlled or to be treated
Exclusion Criteria
* Prior cranial radiotherapy
* Concurrent cytotoxic chemotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ontario Institute for Cancer Research
OTHER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
George Rodrigues
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
George Rodrigues, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
London Regional Cancer Program of the Lawson Health Research Institute
Glenn Bauman, MD
Role: PRINCIPAL_INVESTIGATOR
London Regional Cancer Program of the Lawson Health Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alberta Health Services, Cross Cancer Institute
Edmonton, Alberta, Canada
London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Centre Hospitalier De L'Universite de Montreal
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rodrigues G, Yartsev S, Tay KY, Pond GR, Lagerwaard F, Bauman G. A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases. Radiat Oncol. 2012 Mar 21;7:42. doi: 10.1186/1748-717X-7-42.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16776
Identifier Type: OTHER
Identifier Source: secondary_id
R-10-204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.